O-022Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)

Saved in:

Bibliographic Details
Published in:	Annals of oncology Vol. 30; no. Supplement_4
Main Authors:	Miksad, R, Cicin, I, Chen, Y, Klumpen, H, Kim, S, Lin, Z, Youkstetter, J, Sen, S, Cheng, A, Meyer, T, Kelley, R, Abou-Alfa, G
Format:	Journal Article
Language:	English
Published:	Oxford University Press 01-07-2019
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Author	Klumpen, H Youkstetter, J Abou-Alfa, G Cicin, I Kim, S Kelley, R Sen, S Cheng, A Miksad, R Chen, Y Meyer, T Lin, Z
Author_xml	– sequence: 1 givenname: R surname: Miksad fullname: Miksad, R organization: Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, USA – sequence: 2 givenname: I surname: Cicin fullname: Cicin, I organization: Trakya University, Erdirne, Turkey – sequence: 3 givenname: Y surname: Chen fullname: Chen, Y organization: The Chinese University of Hong Kong, State Key Laboratory in Oncology, Hong Kong, China – sequence: 4 givenname: H surname: Klumpen fullname: Klumpen, H organization: Academic Medical Centre Amsterdam, Amsterdam, The Netherlands – sequence: 5 givenname: S surname: Kim fullname: Kim, S organization: University Hospital of Besancon, Department of Medical Oncology and Clinical Investigational Center CIC-1431, Besançon, France – sequence: 6 givenname: Z surname: Lin fullname: Lin, Z organization: National Taiwan University Hospital, Taipei, Taiwan – sequence: 7 givenname: J surname: Youkstetter fullname: Youkstetter, J organization: Exelixis, Alameda, California, USA – sequence: 8 givenname: S surname: Sen fullname: Sen, S organization: Exelixis, Inc., San Francisco, California, USA – sequence: 9 givenname: A surname: Cheng fullname: Cheng, A organization: Department of Oncology and Internal Medicine, National Taiwan University Hospital, Taipei, Republic of Taiwan – sequence: 10 givenname: T surname: Meyer fullname: Meyer, T organization: Royal Free Hospital, University College London, London, UK – sequence: 11 givenname: R surname: Kelley fullname: Kelley, R organization: Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA – sequence: 12 givenname: G surname: Abou-Alfa fullname: Abou-Alfa, G organization: Memorial Sloan Kettering Cancer Center, New York, New York, USA
BookMark	eNqVkEFuwjAQRa2KSoW2B-huliA1YCdAmyVEqUBCYlH20cQxjSvHjmyHqqw4Qk_SQ_UkNaIX6Gr05_8_I70B6WmjBSEPjI4ZTZMJ6rDgk6Y6stl0TGN2RfpsNk-jZzplPdKnaZxET7NkekMGzr1TSudpnPbJ9zaicbztPDeNcFCiExUYDQtVdo3UP6evpVTSdqXUMFxslusRvFmsBATtawFtHRqQQJZv8tfderEBbyUqMHvgWJojai-1LOEgrOsctAq5KM253aKXQnsHH9LXgNUBNQ-_axEMw4VSnUIbjlgutWkQhqssG92R6z0qJ-7_5i15fMl32SoyXVu0VjZoPwtGizOT4sKkuDApApPkn_FfwyFveg
ContentType	Journal Article
Copyright	The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2019
Copyright_xml	– notice: The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2019
DOI	10.1093/annonc/mdz154.021
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
DocumentTitleAlternate	ESMO 21st World Congress on Gastrointestinal Cancer, 03–06 July 2019, Barcelona, Spain
EISSN	1569-8041
ExternalDocumentID	10.1093/annonc/mdz154.021
GroupedDBID	--- -E4 .2P .86 .I3 .XZ .ZR 08P 0R~ 0SF 1TH 23M 2WC 4.4 482 48X 53G 5GY 5VS 5WA 6J9 70D AAEDW AAJKP AAKUH AALRI AAMVS AAOGV AAPNW AAXUO ABEUO ABIXL ABJNI ABKDP ABLJU ABNKS ABOCM ABQLI ABVKL ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTO ADBBV ADEYI ADHKW ADHZD ADJQC ADOCK ADRIX ADRTK ADVLN ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AEWNT AFETI AFIYH AFOFC AFXEN AGINJ AGKEF AGSYK AHMBA AHXPO AIAGR AIJHB AITUG ALMA_UNASSIGNED_HOLDINGS ALUQC AMRAJ APIBT APWMN AXUDD BAWUL BAYMD BHONS BTRTY BVRKM CDBKE CKLRP COF CS3 CZ4 DAKXR DIK DILTD D~K E3Z EBS EE~ EJD F9B FDB GJXCC GX1 H5~ HAR HW0 HZ~ I09 IH2 IOX J21 KAQDR KOM KOP KQ8 KSI KSN M-Z M41 M49 MHKGH N9A NGC NOYVH NU- O9- OAWHX ODMLO OJQWA OK1 OVD P2P P6G PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 ROL ROX RW1 RXO TCURE TEORI TJX TR2 W8F WOQ X7H YAYTL YFH YKOAZ ZKX ~91
ID	FETCH-oup_primary_10_1093_annonc_mdz154_0213
ISSN	0923-7534
IngestDate	Wed Sep 11 04:47:46 EDT 2024
IsPeerReviewed	true
IsScholarly	true
Issue	Supplement_4
Language	English
License	This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
LinkModel	OpenURL
MergedId	FETCHMERGED-oup_primary_10_1093_annonc_mdz154_0213
ParticipantIDs	oup_primary_10_1093_annonc_mdz154_021
PublicationCentury	2000
PublicationDate	20190701
PublicationDateYYYYMMDD	2019-07-01
PublicationDate_xml	– month: 07 year: 2019 text: 20190701 day: 01
PublicationDecade	2010
PublicationTitle	Annals of oncology
PublicationYear	2019
Publisher	Oxford University Press
Publisher_xml	– name: Oxford University Press
SSID	ssj0006929
Score	4.6819673
SourceID	oup
SourceType	Publisher
Title	O-022Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Volume	30
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtZ3NTqRAEMc7oyYbL2bX1bh-pQ6aaJAINKPDcUQ2M3HUg3PYG4GhUeIKk5nh4slH8En2ofZJtqobGMavjIe9EOhAB6hf-qP6X9WM7cVCmCKODb3JI0O3IyfUg5Zp6s0ots0w5qYVUqBw5-b06lfr3LO9RqPM9Twt-6-WxjK0NUXOfsLaVaVYgOdoczyi1fE4l92vdewvr_MJ1i3GGnVSES0ISFd8klbahrPkdzLKcVpMQ8x276xL7oHbURCJUvk4vMNnNa65Xs-76XfbPU3t8EE6dCTnMaA9JpJQI11HPtakuCvMtGmu1jJwrlQZ3GHPN8lopUBKXwe0i1GaPQT0Bh3XLX0SrzI7Z-lgxvd_mdyPFZjVKpVL-oAZH7BbRJ1UI_ULbIWHqqxTd3XI6Kq6q-OdEMq6T9PiOs6_lIdCFC36iaNTkqV6k18sBSm05fap0hfr2292KirhVpCm-L148hA9kjvOUJHdL7J1f3j_AluysD0k5el596IaMJw4lkoJWbx9ufju8GNVyfG0ChWHWRsC9b-ylWLuAm0F3TfWEOkq-3JZqDO-sz8z7IFkD7IUCvb-Pj1X1MEBMXcIkjjAayQOJHHAoSIOJHGQxVAnDhRxUBBHT5fEAREHJXEwSxxUxMEB8na4xo5-en23o-On-kOVdcVXagnuq1_iq1_i4y_h62wRi8QGg8AeWDxuigEPW7YjolBYJjZGsWOcCsc2rB9sf64qN-e8b4stTzndZouTUS522MI4ynelif8BDR-afA
link.rule.ids	315,782,786,27935,27936
linkProvider	Flying Publisher
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=O-022Outcomes+based+on+Albumin%E2%80%90Bilirubin+%28ALBI%29+grade+in+the+phase+3+CELESTIAL+trial+of+cabozantinib+versus+placebo+in+patients+with+advanced+hepatocellular+carcinoma+%28HCC%29&rft.jtitle=Annals+of+oncology&rft.au=Miksad%2C+R&rft.au=Cicin%2C+I&rft.au=Chen%2C+Y&rft.au=Klumpen%2C+H&rft.date=2019-07-01&rft.pub=Oxford+University+Press&rft.issn=0923-7534&rft.eissn=1569-8041&rft.volume=30&rft.issue=Supplement_4&rft_id=info:doi/10.1093%2Fannonc%2Fmdz154.021&rft.externalDocID=10.1093%2Fannonc%2Fmdz154.021
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0923-7534&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0923-7534&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0923-7534&client=summon